• STAT Plus: Disarm Therapeutics bought by Lilly for $135 million

    7 days ago - By STAT

    Disarm Therapeutics, a Cambridge biotechnology firm working on new potential drugs for neurological diseases such as ALS and multiple sclerosis, will be bought by the pharmaceutical giant Eli Lilly and Company for $135 million up front.
    Under the deal announced Thursday, investors in the four-year-old, privately held biotech could reap up to $1.225 billion in additional payments, depending on how well Lilly does developing and marketing new medicines resulting from the acquisition. Continue to STAT Plus to read the full story...
    Read more ...